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EDITORIL
Does autocrine growth factor secretion form part of a mechanism which
paradoxically protects against tumour development?
T Dawson and D Wynford-Thomas
CRC Thyroid Tumour Biology- Research Group, Department ofPatholog., University of Wales College ofMedicine, Heath Park,
CardiffCF4 4X.N, UK.
Summary Autocrine growth factor secretion has classically been considered as a mechanism by which tumour
cells achieve autonomous growth. However, there is now considerable evidence that autocrine circuits operate
in the growth regulation of normal adult tissues. Here we consider the possible advantages to the normal
epithehal cell of utilising such an external growth factor circuit and suggest that autocrine growth factor
secretion, when viewed in a multicellular context, could paradoxically form part of a mechanism for
preventing tumour development.
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Background
The autocrine hypothesis of growth regulation was first pro-
posed to account for growth factor independence in tumours
(Sporn and Todaro. 1980), and much evidence has accumu-
lated to support this idea (Sporn and Roberts, 1985; Cross
and Dexter, 1991; Daughaday and Deuel, 1991). Indeed, it is
now realised that the original concept was too restnrctive and
that autocrine circuits also function as a component of nor-
mal growth-regulatory mechanisms in many adult tissue
types. in which the primary mitogen appears to induce local
autocrine production of a cooperating non-tissue-specific
secondary mitogen (Coffey. 1987; Bortz et al.. 1988; Cross
and Dexter, 1991; Daughaday and Deuel, 1991). However,
while there is an obvious selective growth advantage to a
tumour cell secreting its own growth factors, the functional
benefits to normal cells are less apparent. Our studies into
the role of one of the major locally produced autocrine
agents. insulin-like growth factor I (IGF-I), in normal and
neoplastic thyroid growth has led us to critically re-examine
the classical view of autocrine stimulation as it relates to the
single cell and propose an extension of the hypothesis which
takes into account growth regulation in a multicellular con-
text.
Aside from a weak insulin-like anabolic effect, the major
physiological action of IGF-I appears to be as a regulator of
cell proliferation in both epithelial and mesenchymal tissues.
In this role it acts as a powerful, but relatively non-tissue-
specific, 'permissive' mitogen which is required for a maximal
proliferative response to more highly tissue-specific trophic
factors such as platelet-denrved growth factor (PDGF), fibro-
blast growth factor (FGF) or thyroid-stimulating hormone
(TSH). In cell kinetic terms it fulfils the function of a general
progression factor' for cells previously stimulated by a more
specific 'competence' factor (Leof et al., 1982). Although the
liver is a major site of synthesis for systemically circulating
IGF-I. there is also significant local production of the growth
factor by both epithelial and stromal elements (D'Ercole et
al., 1984; Han et al., 1987; Hansson et al., 1988). In partic-
ular, many tissue-specific hormones, such as oestrogens.
adrenocorticotrophic hormone (ACTH), luteinising hormone
(LH). follicle-stimulating hormone (FSH) and TSH appear to
induce or modulate local IGF-I expression in their target
tissues in addition to their direct actions (Holly and Wass.
1989: Sara and Hall. 1990: LeRoith and Roberts. 1991).
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The existence of an IGF-I autocrine circuit in adult
thyroid tissue is supported by data showing that thyroid
follicular cells both produce IGF-I (Ollis et al., 1989; Tode et
al., 1989) and express cognate receptors for this growth
factor (Tode et al., 1989; Yashiro et al., 1989), as well as
requiring a minimum level of IGF-I for mitogenic response in
vitro to TSH (Tramontano et al., 1986; Williams et al., 1988).
Further studies have demonstrated that TSH stimulates IGF-
I secretion (Tode et al., 1989) and reduces specific IGF-I-
binding protein (Wang et al., 1990), both of which would be
predicted to increase local free IGF-I concentration. Together
these data suggest that IGF-I plays a key physiological role
in synergising with the TSH stimulus to promote thyrocyte
growth and that part of this mechanism involves the induc-
tion of an IGF-I autocrine circuit by TSH in the target
tissue. Furthermore, there is compelling evidence that aber-
rant production of IGF-I is involved in the genesis of thyroid
tumours (follicular adenomas), in many cases as a result of
the oncogenic activation of the ras family of signal transduc-
tion proteins (Lemoine et al., 1989; Suarez et al., 1990;
Dawson et al., 1995). These finding are in accordance with a
general shift in emphasis over recent years, from an endo-
crine to a paracrine or autocrine role for IGF-I in growth
regulation.
What are the advantages of an autocrne circut?
In evolutionary terms, the relatively non-tissue-specific
mitogenic action of IGF-I suggests that it formed part of a
primordial mechanism upon which higher orders of control
have been successively grafted to provide independent regula-
tion of specialised tissue types. One possible reason for
retaining this primitive system is that it allows for integration
of multiple mitogenic signals. such that a combination of
tissue-specific primary factors can stimulate cell growth by
acting through a common final pathway - the locally pro-
duced mitogen. Teleologically however, it seems unnecessary
for such a mechanism to involve an external loop. since
signal integration could equally well be served by conver-
gence of the signalling pathways at an intracellular level.
'Exteriorisation' is 'costly' in terms of the high production
levels of growth factor required to overcome diffusion effects
and the need to maintain an additional receptor pathway. so
that, with regard to the individual normal cell, the classical
autocrine mechanism seems to offer little overall benefit. The
evolutionary advantage of such a system must therefore pre-Is au rhine g hfdactor seaetion prie?
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sumably lie in the element of cell-cell communication which
it affords, implying that it has evolved not so much for
autocrine but for paracrine stimulation.
One important aspect of this is, undoubtedly. that produc-
tion of a non-specific mitogen. such as IGF-1, by growing
epithelial cells may stimulate associated stromal elements not
otherwise influenced by the primary signal, thereby providing
for coordinated growth of the tissue. However, if this were
the only raison detre for an exteriorised signal, why should
epithelial cells produce a growth factor which is also auto-
stimulatory. rather than an agent more specific for the
stromal component? The answer may be that paracrine con-
trol by IGF-I operates not just in the conventional hetero-
typic role, to coordinate stroma with epithelium, but also in
a homotypic mode, to coordinate growth within the epithe-
lium itself. The essential tenet of this 'homotypic paracrine
hypothesis is that the concentration of IGF-I to which an
epithelial cell is exposed depends not only on its own auto-
crine secretion but also on that of its neighbours. such that
the critical concentration required for response to its tissue-
specific mitogen cannot be achieved by a single cell but
requires the cooperative secretory activity of the epithelial
population en masse.
Classical Ps cooperative autocrine circuits
Autocrine circuits have conventionally been considered in
terms of the individual cell in isolation. In vivo however, the
steady-state extracellular concentration of an autocrine-
derived growth factor to which any given cell in a tissue is
exposed may be expected to depend not only on its own
secretion rate but also on that of its immediate neighbours.
The extent of this influence will be dictated by the effective
range of the factor in the tissue, determined, inter alia. by the
rate of diffusion through the extracellular fluid (ECF) and
the rate of inactivation (through proteolysis and sequestra-
tion by soluble and matrix-bound binding proteins). This is
of course difficult to assess expenrmentally, but since it is
generally accepted that significant paracrine IGF-I communi-
cation operates between stroma and epithelium. it seems
reasonable to infer that a significant paracrine contribution
also exists between neighbouring epithelial cells. We propose
that such cooperation is in fact essential to allow the IGF-I
concentration in the ECF to reach the required threshold to
permit a mitogenic response to the primary mitogenic signal
,e.g. TSH).
Paracrine signalling is undoubtedly the key to explaining
the evolutionary benefit of an extracellular loop in the
mitogenic response since it adds a tissue-level dimension
which is not afforded by a purely intracellular signalling
pathway. Although the original selective pressure for evolu-
tion of paracrine control may have been its heterotypic role,
we argue that homotypic regulation provides major addi-
tional advantages through its inherent 'smoothing' effect on
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proliferation rates across the epithelium. Firstly, this will
tend to counteract the innate (epigenetically determined) cell-
to-cell variability in responsiveness to the primary mitogen
often seen in hormonally regulated epithelia (Studer et al..
1989). which might otherwise lead to preferential growth of
the more sensitive cells. Secondly, and more importantly. it
provides an intrinsic safeguard against the development of
hyperproliferative clones resulting from somatic mutations
mimicking mitogen stimulation, i.e. neoplasia. This aspect is
particularly well illustrated in thyroid follicular cell tumori-
genesis.
Homotvpic paracrine control and tumour development
There is persuasive evidence from clinical and experimental
tumour studies, supported by in vitro gene transfer experi-
ments, that activation of ras p21 protein by point mutation is
a frequent initiating even in thyroid follicular cell tumori-
genesis (Lemoine et al.. 1989: Suarez et al.. 1990; Bond et al..
1994). Paradoxically however, in vivo models of experimental
thyroid tumorigenesis. in which ras mutations are generated
by mutagens or by direct intraglandular injection of ret-
rovirus vectors encoding mutant ras. give an unexpectedly
low yield of tumours, unless measures are also taken to
increase the overall level of mitotic activity of the gland. e.g.
bv raising serum TSH levels (Lemoine et al.. 1988; Portella et
al.. 1989: Thomas et al., 1991).
This of course represents the phenomenon of tumour pro-
motion by a physiological growth stimulus, a concept
originally proposed by Beatson and elaborated in relation to
the thyroid by Doniach (1958, 1970). However, the underly-
ing mechanisms of promotion have remained controversial.
A popular explanation is that the initiating mutation is
insufficient by itself to induce growth in the presence of
normal levels of primary mitogen. but if clonal expansion
occurs under the influence of a physiological stimulus, further
mutations occur which allow eventual autonomy. Alterna-
tively. it has been suggested that mutation marginally inc-
reases cellular sensitivity to the primary mitogen. thereby
providing a selective growth advantage in states of physio-
logical stimulation. The homotypic paracrine hypothesis,
however, provides a novel explanation for this phenomenon.
in which tumour promotion is seen to be simply an innate
consequence of cooperative autocrine control.
This may be explained in the following manner. During
physiological growth. part of the response of the normal cell
to the primary mitogen (e.g. TSH) involves induction of a
secondary mitogen, such as IGF-I, in an autocrine loop
(Figure 1). Tumour cells, however, appear to express this
autocrine loop independent of primary mitogen stimulation
or at least independent of any increase in mitogen concentra-
tion above normal basal levels (Figure 1). This is supported
by work from our own and other laboratories which have
demonstrated increased IGF-I secretion by tumour cells com-
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Figure I Schematic diagram showing a normal cell undergoing physiological growth in which part of the response to an increase
in extracellular concentration of pnrmary mitogen (e.g. TSH) involves induction of a secondary mitogen (e.g. IGF-I) in an autocrine
loop. Tumour cells appear to express this autocrine loop independent of any increase in primary mitogen concentration, as a
response to inappropriate activation of intracellular signalling molecules, such as ras. which mimic the action of the primarv
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Fue 2 Comparisons and contrasts between 'classical' and cooperative autocrine (homotypic paracrine) control. Normal cells are
represented as polygons, tumour cells as irregular outlines labelled 'r'. Production of secondary mitogen is shown by graduated
shading (indicating diffusion gradients). and in quiescent cells its absence (or basal level) is indicated by an empty dotted circle
around the cell. (a) A tissue in which there is no active growth (basal level of primary mitogen). In both models, individual normal
cells are quiescent and do not produce a significant amount of secondary mitogen (empty dotted circles). (b) A tissue which is
undergoing physiological growth induced by an increase in primary mitogen concentration. In both models, normal cells actively
produce a secondary mitogen in response to this stimulus. According to the classical autocrine model, cells act independently to
generate the required critical concentration of the secondary mitogen in the ECF via an entirely 'private' autocrine loop. In the
cooperative (homotypic paracrine) model, however, this concentration can only be achieved by the combined secretory activity of
neighbounrng cells (shown by the darker shading in overlapping areas) which ensures an interdependent, tissue-wide recruitment of
cells into growth. (c) Unstimulated tissue (basal primary mitogen level) in which one cell has acquyred an oncogenic mutation which
triggers inappropnate secretion of the secondary mitogen. mimicking physiological growth stimulation. The classical autocrine
model predicts that this cell can act independently through its private autocrine loop to generate a critical mitogenic concentration
and achieve autonomous growth, eventually forming a tumour. In the cooperative model however, growth of the mutant cell is
frustrated by the inability to generate this critical concentration in the presence of quiescent normal cells (shown by the light
shading in overlapping areas). Growth of the potential tumour cell is therefore prevented.
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Figre 3 Schematic illustrating tumour promotion by a physiological growth stimulus as predicted by the homotypic paracrine
hypothesis. (a) Unstimulated tissue (basal primary mitogen level) containing a single tumour cell inappropriately secreting
secondary mitogen but unable to grow autonomously. A period of physiological growth, induced by elevation of the primary
mitogen, allows normal cells to proliferate and stimulates their production of secondary mitogen, their combined secretory activity
thereby also supporting clonal expansion of the tumour cell. Subsequently, although the physiological growth stimulus subsides and
normal cells return to their unstimulated state (b), the tumour cell clone has now reached a 'critical mass' which can generate a
sufficient local concentration of the secondary mitogen to thereafter maintain growth independent of increased mitogen stimulation
(c),
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pared with their normal counterparts (reviewed by Macauley,
1992). This aberrant secretion, though. does not appear to be
due to any primary abnormality of the IGF-I gene itself but
represents an appropriate response to inappropriate consti-
tutive activation of intracellular signalling molecules. such as
ras. which mimic the effect of an increase in concentration of
the primary mitogen.
According to the classical autocrine hypothesis. aberrant
secretion of the secondary mitogen should provide the selec-
tive advantage required to allow the mutant cell to grow
autonomously and form a tumour (Figure 2c). This, how-
ever, does not explain the phenomenon of tumour promotion
by a physiological growth stimulus as described above. We
propose instead that proliferation of a single mutant cell is
frustrated since, even though its own IGF-I production is
elevated, it cannot achieve the required mitogenic threshold
concentration in isolation against the dilutional effects of the
surrounding milieu populated by quiescent low-output nor-
mal cells (Figure 2c and 3a). Tumour development is there-
fore effectively suppressed. However, if a period of physio-
logical growth occurs. clonal expansion of the mutant cell
will be supported by the cooperative secretory activity of
neighbouring normal cells (Figure 3b). Eventually the mutant
clone will reach a 'critical mass' whereupon it can generate
sufficient IGF-I concentration in its microenvironment to
sustain autonomous growth without the cooperation of adja-
cent mitogen-stimulated normal cells (Figure 3c). Thus, the
tumour will be able to continue to grow even after the
primary mitogenic stimulus has returned to basal levels.
In this model therefore, the promoter is seen to play no
direct signalling role but merely alters the clonal composition
of the tissue, thereby circumventing homotypic paracrine
control. Promotion as an inherent consequence of expansion
of tumour mass could of course also operate by the recipro-
cal model, originally proposed by Wheldon (1975), in which
tumour cells fail to secrete an inhibitory paracnrne factor, the
concentration of which therefore declines as the centre of the
clone becomes progressively further from the normal sur-
rounding cells. As yet, however. no good candidate effectors
for such a model have been identified.
In addition to providing an explanation for the very low
yield of experimental thyroid tumours in the absence of
primary mitogen stimulation. this hypothesis also accounts
for the well-documented higher incidence of human thyroid
tumours in iodine-deficient goitrous areas of the World (Shi
et al., 1991). Presumably those tumours which rise without
any apparent preceding hyperplasia are the result of rare
oncogenic events which either bypass the requirement for
IGF-I or raise output to a level above the maximum achiev-
able by trophic hormone stimulation, which is then sufficient
to circumvent the limitation normally imposed by homotypic
paracrine control.
ConclusioIs
We propose that, while the classical hypothesis of autocrine
growth factor secretion was originally elaborated in relation
to the malignant transformation of cells. autocrine circuits
actually form part of a mechanism which coordinates tissue
growth in response to the primary mitogen and paradoxically
limits the development of neoplastic clones. This hypothesis
fits all existing data and provides a cogent explanation for
the hitherto poorly explained phenomenon of tumour promo-
tion by physiological growth stimulation. Although formu-
lated in relation to the thyroid model. we can see no reason
why this mechanism should not have evolved to perform a
similar function in other tissues where autocnrne circuits form
part of normal growth regulation.
Abbreviaion: TSH. thyroid-stimulating hormone. IGF-I. insulin-like
growth factor I: ACTH. adrenocorticotrophic hormone: PDGF.
platelet-derived growth factor: FGF. fibroblast growth factor(s): LH,
luteinising hormone: FSH. follicle-stimulating hormone.
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